| |DECEMBER 20239Silo Pharma, Inc., a developmental stage biopharmaceutical company focused on combining traditional therapeutics with psychedelic research, announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, which was chosen as the delivery mechanism for Silo's intranasal therapeutic drug SPC-15."We began a collaboration with Medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug SPC-15. Based on successful outcomes from these studies, we have selected Medspray's Spray Technology for our formulation," said Eric Weisblum, Chief Executive Officer of Silo Pharma. "As part of our manufacturing and sales contract, we have obtained exclusive rights to its spray mist technology for use with multiple indications including post-traumatic stress disorder (PTSD) and anxiety, as well as Alzheimer's disease and anorexia. We believe these rights are a valuable asset that can support Silo's continuing research and development of novel therapeutics."Medspray develops and manufactures a soft mist nasal spray technology using silicon microchip-based spray nozzles. A formulation-specific, customized aerosol plume that is designed to allow for better deposition in the relevant region of the nasal cavity, thereby reducing levels of systemic absorption, as per Silo Pharma. The medication distribution from the nose to the brain has been optimized for patient safety and therapeutic administration.SPC-15 is a new 5-HT4 receptor agonist that uses biomarkers to treat PTSD, anxiety, and other stress-related affective disorders. SPC-15 is being researched for use as an intranasal medicine. SPC-15 may be eligible for the FDA's simplified 505(b)(2) regulatory process for medication registration if clinical trials are successful. Silo Pharma is collaborating with Columbia University on preclinical investigations of SPC-15 under a funded research agreement and option. POWith the release of its new guideline on the prevention and management of wasting and nutritional oedema (acute malnutrition), the World Health Organization (WHO) is furthering the worldwide fight against acute malnutrition in children under the age of five. This landmark is an important response to the ongoing global challenge of acute malnutrition, which affects millions of children worldwide. In 2015, the world committed to achieving the Sustainable Development Goals (SDGs), including the ambitious target of eliminating malnutrition in all of its forms by 2030. However, despite these commitments, the proportion of children with acute malnutrition has persisted at a worrying level, affecting an estimated 45 million children under five worldwide in 2022, as per pharmabiz. Approximately 7.3 million children will be treated for severe acute malnutrition (SAM) by 2022. Despite greater treatment coverage, children with SAM in many of the worst-affected nations continue to lack access to the complete range of care required for recovery. The Global Action Plan (GAP) on Child Waste recognizes the need for revised normative advice to help countries avoid and manage acute malnutrition. WHO responded to this call to action by developing a comprehensive guideline that includes evidence-based recommendations and good practice statements, as well as implementation advice and resources. "This guideline helps to support countries to prevent and manage acute malnutrition with a specific emphasis on the continuum of care to deliver the best services possible for children and their families." said Dr Tedros. "We are calling for more integration of nutrition services into health systems and the strengthening of those health systems. This is a more comprehensive approach to address the complex issue of acute malnutrition in children than ever before." POSILO PHARMA AND MEDSPRAY ENTER INTO AGREEMENT FOR PTSD TREATMENTWHO INTRODUCES NEW GUIDELINE TO ADDRESS MALNUTRITION IN CHILDRENTOP STORIES
< Page 8 | Page 10 >